667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY
|
|
- Katrina Richard
- 5 years ago
- Views:
Transcription
1 667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY Contents Introduction... 1 Patient Education for People with Type 2 Diabetes... 2 Dietary Advice for People with Type 2 Diabetes... 2 Self-monitoring... 2 Blood Glucose Lowering/Treatment Intensification... 3 General guidance on intensification... 3 Oral treatment... 4 Oral agents: Quick reference for selecting an agent... 5 Injectable treatment... 6 Structured Education when Initiating a GLP-1 or Insulin Therapy... 7 Starting Insulin Therapy in People with Type 2 Diabetes... 8 References... 9 Appendix 1: Patient Information on Home Blood Glucose Testing in Type 2 Diabetes Introduction In December 2015, NICE updated its clinical guideline on Type 2 Diabetes (NG28). This encompasses all aspects of patient management including not only blood glucose control but also lipid management, anti-thrombotic therapy and blood pressure control. This clinical guideline represents the local adaptation of the above NICE guideline in relation to blood-glucose-lowering therapy and was developed in collaboration between Buckinghamshire Healthcare Trust (BHNSHT) and Buckinghamshire Clinical Commissioning Group. The application of the recommendations in this guideline should always be considered alongside the individual clinical need and personal preferences of the patient. Clinical support is available from the Community DSN Advice and Guidance telephone line: (Monday - Friday 10-16:00 hours). All supporting documents mentioned in the guideline can be found on the Medicines Management website: See also: Guideline 109FM Glucagon-Like Peptide-1 (GLP-1) Agonists for Adults with Type 2 Diabetes Guideline 667FM of 11 Uncontrolled if printed
2 Patient Education for People with Type 2 Diabetes Structured education is an integral part of diabetes care and patients and carers should be informed of this offer at the time of diagnosis, with annual reinforcement and review. Referral to online and face to face structured education can be done through the Live Well, Stay Well website or by healthcare professionals (HCPs) making a referral by . Dietary Advice for People with Type 2 Diabetes Provide in a form that is sensitive to the person s needs, culture and beliefs, being sensitive to their willingness to change, and effects on their quality of life. Integrate with diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity. Discourage use of foods marketed specifically for people with diabetes. Include in Discussion General advice for healthy eating: include high-fibre, low-glycaemic index sources of carbohydrate include low-fat dairy products and oily fish control the intake of foods containing saturated fats and trans fatty acids. Limited substitution of sucrose containing foods for other carbohydrate is allowable, but care should be taken to avoid excess energy intake. Refer using local dietetics pathway if further help needed. Action Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. Individualise recommendations for carbohydrate and alcohol intake, and meal patterns aim to reduce risk of hypoglycaemia, particularly if using insulin or insulin secretagogues. Initial body weight loss target = 5 10% in an overweight person: lesser amounts are still beneficial losing more weight in the longer term has metabolic benefits. Special Circumstances Special needs for inpatients with type 2 diabetes will be dealt with by dieticians. Self-monitoring Please refer to the CCG Patient Information on Home Blood Glucose Testing in Type 2 Diabetes leaflet (appendix 1) for ongoing monitoring information. Agree level and ongoing frequency of monitoring requirements; with each individual patient when on an insulin secretagogue or insulin. Testing may also be required when patient is on steroid therapy or to assess post prandial blood glucose readings (see above). Guideline 667FM of 11 Uncontrolled if printed
3 Blood Glucose Lowering/Treatment Intensification General guidance on intensification Initiation: Start treatment if HbA1c >48 mmol/mol note if HbA1c is very high (e.g. >75 mmol/mol)/patient has significant osmotic symptoms/acute or sub-acute onset over weeks ensure that the diagnosis is type 2 diabetes. Temporary treatment with insulin may be necessary *. Individualise HbA1c (see below) - set goals for each patient. Following diagnosis HbA1c should be done at 3 months after each intensification until individual goal of HbA1c reached see above. Consider checking HbA1c every 6-12 months, once stable. If there is a discrepancy between self-monitoring and HbA1c, and in scenarios where HbA1c may not be reliable (see page 4), seek advice from community DSNs/Diabetes Centre at Buckinghamshire Healthcare NHS Trust. For individual drug category see When preferred? When to exercise caution? Decide goals when adding agents: Stop treatment which has not had desired effect. Offer self-monitoring routinely to people on sulfonylurea, insulin and when using steroids (see Self-monitoring Pathway). Select oral agent according to quick reference guide (refer to individual drug safety information before prescribing). Individualised HbA1c Tight control Modest control Recent diagnosis Long life expectancy Low risk of hypoglycaemia On oral agents that don t cause hypoglycaemia Few vascular complications Good resources/compliance with follow up Frail elderly Long disease duration Shorter life expectancy High risk of hypoglycaemia Hypoglycaemia with optimum insulin Established vascular complications Poor resources/compliance with follow up Example: In a frail 85 year old lady with risk of fall aim for modest control. In a 50 year old lady, with no co-morbidity aim for tight control. * Please seek advice from community specialist nurses ( )/secondary care if there is diagnostic uncertainty or uncertainty about target HbA1c. Guideline 667FM of 11 Uncontrolled if printed
4 Oral treatment Choice of medication is dependent on patient parameters please see oral agents quick reference on page 5. Monotherapy: HbA1c >48 (start treatment) Aim for HbA1c of 48 (53 when on sulfonylurea) Preferred choice Alternatives Metformin Sulfonylurea* Pioglitazone SGLT-2 inhibitor DPP-4 inhibitor Dual Therapy (first intensification): HbA1c >58 on one drug Aim for HbA1c of 53 If on metformin If not on metformin Sulfonylurea* Pioglitazone SGLT-2 inhibitor DPP-4 inhibitor Sulfonylurea* + Pioglitazone Sulfonylurea* + SGLT-2 inhibitor Sulfonylurea* + DPP-4 inhibitor Pioglitazone + DPP-4 inhibitor (this combination is not licensed, under pioglitazone, but is mentioned as a treatment combination by NICE) Triple Therapy (second intensification): HbA1c >58 on two drugs Aim for HbA1c of 53 If on metformin+ sulfonylurea Other combinations Add SGLT-2 inhibitor Add pioglitazone Add DPP-4 inhibitor Consider insulin or GLP-1 after two drugs if not on metformin. Repaglinide is an alternative but has modest efficacy and compliance may be an issue as given three times a day. HbA1c is in mmol/mol. * Sulfonylureas (SUs) are cheaper than SGLT-2/DPP-4 inhibitors, however, self-monitoring is essential with SUs. Second and third choices are dependent on patient s clinical parameters. Guideline 667FM of 11 Uncontrolled if printed
5 Oral agents: Quick reference for selecting an agent Biguanide (Metformin) When preferred? First line unless contraindicated Weight neutral Probable long term cardiovascular risk reduction Safe in pregnancy Caution Renal impairment (submaximal dose <45, stop at egfr <30) Gastrointestinal side effects (use MR formulation before discontinuing) Vitamin B 12 deficiency (routine measurement not recommended) Consider using metformin modified release if gastro-intestinal symptoms experienced with standard release metformin Sulfonylurea (Gliclazide) When preferred? Early stages of diagnosis Low BMI (ensure correct type of diabetes diagnosed) Caution Hypoglycaemia avoid in frail, elderly, and if in an occupation where hypoglycaemia is risky Weight gain Thiazolinedinedione (Pioglitazone) When preferred? Caution Probable long term cardiovascular risk Heart failure, fluid retention reduction Osteoporosis at risk, or established Reduces triglyceride level Bladder cancer personal or family Can be used in renal impairment history Weight gain SGLT-2 inhibitor (First line: Dapagliflozin; Age >75: Empagliflozin; Age >85: Canagliflozin) When preferred? Caution Weight neutral - in high BMI patients may result in weight loss Euglycaemic ketosis (routine ketone testing not recommended but patient When hypoglycaemia is a concern should be warned of symptoms) Glucose independent cardiovascular Genitourinary infections (fungal, bacterial) benefit Dehydration if co-prescription with Can be used with insulin to limit weight diuretics gain and reduce insulin dose Renal impairment: May be commenced for all three therapies if egfr >60 ml/min. If already taking empagliflozin or canaglifozin they can be continued with egfr ml/min. Dapagliflozin must be discontinued if egfr <60 ml/min. DPP-4 inhibitor (Sitagliptin) When preferred? Weight neutral Early stages of diagnosis When hypoglycaemia is a concern May be used in renal failure (see dose reduction) Consider stopping in foot complications (e.g. ulcers increased risk of toe amputations) Caution High risk of pancreatitis: e.g. personal or family history, high triglycerides Needs dose reduction according to stage of renal disease (sitagliptin 25 mg/day for stages 4, 5 chronic kidney disease (CKD)) Guideline 667FM of 11 Uncontrolled if printed
6 Injectable treatment GLP-1 mimetic (See GLP-1 guidance) Consider when: Three drugs not tolerated/contraindicated/ effective or not achieving HbA1c goal on three oral drugs add GLP-1 mimetic in any of these scenarios: 1. If BMI >35 kg/m 2 (lower BMI for Asian/minority ethnic groups) 2. Obesity related physical/psychological problems at lower BMI 3. Any BMI if occupational implications to starting insulin Note: Patients may continue on metformin and/or sulfonylurea. For start/co-prescription with insulin: Community diabetes nurse referral. Agents: 1. First line liraglutide (Victoza ) 2. Alternative weekly preparation: Bydureon (Exenatide weekly) Caution: 1. High risk of pancreatitis: personal/family history, high triglycerides, alcohol abuse 2. Renal impairment: Avoid liraglutide at egfr <15 (Bydureon at egfr <50) 3. Severe hepatic impairment 4. Long disease duration: Efficacy will be reduced Insulin (See Insulin guidance) Consider when: Three drugs not tolerated/contraindicated/ effective. (For patients not on metformin may be considered after two drugs.) Insulin treatment may be necessary if HbA1c is very high/ diagnosis is uncertain/if there is hyperglycaemic emergency. Offer structured education Self-monitoring Metformin, and/or SGLT-2 inhibitors may be continued with insulin SU, DPP-4 may be used with basal insulin but unlikely to be of benefit with prandial or mixed insulin For start/co-prescription with GLP-1 mimetic: Community diabetes nurse referral Agents: (see insulin flowchart) 1. If HbA1c <75 mmol/mol, human intermediate acting insulin (e.g. NPH) OD/BD with other hypoglycaemics 2. If HbA1c >75 mmol/mol, human NPH insulin OD/BD with short acting insulin or analogue pre-mixed insulins where multiple injections may be challenging 3. Analogue pre-mixed insulin if requiring mixed insulin. Consider analogue basal insulin e.g. Lantus if hypoglycaemia on NPH or once daily administration required 4. Use basal bolus regimen in younger patients/flexible lifestyle Caution: 1. Higher risk of hypoglycaemia Guideline 667FM of 11 Uncontrolled if printed
7 Structured Education when Initiating a GLP-1 or Insulin Therapy: When starting insulin or GLP-1 therapy, use a structured programme that encompasses: structured programme of education continuing telephone support frequent self-monitoring dose titration to target dietary understanding management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional Guideline 667FM of 11 Uncontrolled if printed
8 Starting Insulin Therapy in People with Type 2 Diabetes If other measures do not keep HbA1c to <59 mmol/mol (or other agreed target), discuss benefits and risks of insulin treatment. Initiate with structured programme (as specified in Insulin Self-Management for Adults with Type 2 Diabetes 1 ) HbA1c <75 mmol/mol 2 HbA1c 75 mmol/mol 2 Begin with human NPH 3 insulin, e.g. Insulatard or Humulin I taken at bedtime or twice-daily according to need Consider basal-bolus regimen tailored to the needs of the individual, e.g. glulisine (Apidra ) + NPH Consider twice-daily analogue pre-mixed (e.g. Novomix 30). A oncedaily regimen may be an option. Alternatively, consider a once-daily long-acting insulin analogue, e.g. Lantus or biosimilar (AI) if: the person needs help with injecting insulin and a long-acting insulin analogue would reduce injections from twice to once-daily, or the person s lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes, or the person would otherwise need twice-daily basal insulin injections plus oral glucose lowering drugs, or the person cannot use any of the NPH insulin devices. Note: Sulfonylurea should be reviewed when starting insulin. Stop if patients are on short acting or pre-mixed insulin. Continue metformin and/or SGLT-2 inhibitors with insulin if tolerated. Review GLP-1 agonist when starting insulin. Insulin can be added to a GLP-1 agent and vice versa. Please see guideline 109FM. 1 Aylesbury Vale and Chiltern CCG, Insulin Self-Management for Adults with Type 2 Diabetes (service specification), September Or individually agreed target. 3 NPH = Neutral Protamine Hagedorn Guideline 667FM of 11 Uncontrolled if printed
9 References 1. NICE Type 2 diabetes in adults: management: guidance (NG28) 2. MHRA: SGLT-2 inhibitors: updated advice on the risk of diabetic ketoacidosis. Drug Safety Update, Volume 9, Issue 9, April MHRA: Canagliflozin (Invokana, Vokanamet ): signal of increased risk of lower extremity amputations in trial in high cardiovascular risk patients. Drug Safety Update, Volume 9, Issue 11, June MHRA: SGLT-2 Inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes). Drug Safety Update, Volume 10, Issue 8, March See also: Guideline 109FM Glucagon-Like Peptide-1 (GLP-1) Agonists for Adults with Type 2 Diabetes Guideline Title Management of Type 2 Diabetes: Blood-Glucose-Lowering Therapy Guideline Number 667FM Version 5.1 Effective Date January 2018 Review Date January 2021 Amended June 2018 Approvals: Diabetes Guidelines Group 9 th October 2017 Formulary Management Group 2 nd September 2015 Medicines Management 9 th November 2017 and 9 th April 2018 Subcommittee Clinical Guidelines Subgroup 10 th November 2017 and 8 th June 2018 Accountable Care System 6 th December 2017 Medicines optimisation Board Author/s Dr Chitra Ballav, Consultant, Diabetes and Endocrinology Breda Cronnolly, Medicines Optimisation & Interface Pharmacist Gill Dunn, Diabetes Specialist Nurse, Buckinghamshire CCG SDU(s)/Department(s) responsible for updating the guideline Diabetes and Endocrinology Aylesbury Vale and Chiltern CCGs Uploaded to Intranet 9 th January 2018 and 25 th June 2018 Buckinghamshire Healthcare NHS Trust/Buckinghamshire Clinical Commissioning Group Guideline 667FM of 11 Uncontrolled if printed
10 Appendix 1: Patient Information on Home Blood Glucose Testing in Type 2 Diabetes Guideline 667FM.5 10 of 11 Uncontrolled if printed
11 Guideline 667FM.5 11 of 11 Uncontrolled if printed
Dept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationArrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationSTEP 3: Add or Substitute with one of
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationDiabetes, Type 2 Management
CLINICAL GUIDELINE Diabetes, Type 2 Management A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationPLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
More informationClinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures
Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More informationNICE guideline Published: 2 December 2015 nice.org.uk/guidance/ng28
Type 2 diabetes in adults: management NICE guideline Published: 2 December 2015 nice.org.uk/guidance/ng28 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationThere have been important changes in diabetes care which may not be covered in undergraduate textbooks.
Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationInitiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital
Initiating Injectables in Type 2 Diabetes Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Increasing levels in delivery of diabetes care Complex Care support 3 3.1 People with diabetes
More informationType 2 Diabetes Therapies and Management: An Educational Toolkit
University Hospitals of Leicester, Department of Diabetes and Leicester Diabetes Centre: Type 2 Diabetes Therapies and Management: An Educational Toolkit Acknowledgements This document is designed to enable
More informationDIABETES INDICATIONS FOR INSULIN
DIABETES INDICATIONS FOR INSULIN 1 Introduce the likely need for insulin in the future early on as part of patient education Emphasise that it is the pancreas that fails not the patient Assess if greater
More informationPERIOPERATIVE DIABETES GUIDELINE
PERIOPERATIVE DIABETES GUIDELINE This Guideline does not replace the need for the application of clinical judgment in respect to each individual patient. Background Diabetes mellitus is estimated to affect
More informationInsulin Therapies: An Educational Toolkit
University Hospitals of Leicester, Department of Diabetes and Leicester Diabetes Centre: Insulin Therapies: An Educational Toolkit This document is designed for use by those trained and competent in insulin
More informationthe person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and
Exenatide (Byetta) and Liraglutide (Victoza) prescribing guidance: Notes for initiation in primary care These incretin mimetics are given by subcutaneous injection once or twice daily. They have similar
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Bulletin Glucagon-like peptide 1 (GLP-1) receptor agonist review
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2017 Review February 2020 Bulletin 245 - Glucagon-like peptide 1 (GLP-1) receptor agonist review JPC Recommendations:- Place in therapy
More informationThe principles of insulin adjustment guidance
The principles of insulin adjustment guidance Tips for insulin titration Blood glucose (BG) monitoring is needed to help identify the efficacy of treatment in diabetes. Monitor blood glucose according
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationType 2 diabetes in adults
Internal Clinical Guidelines Team Final version : management Clinical Guideline Update (NG28) Methods, evidence and recommendations December 2015 Commissioned by the National Institute for Health and Care
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having an OGD or Bronchoscopy This guidance is provided to assist with your preparation for your endoscopic procedure. If you feel unclear about how
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Overarching Shared Care Guideline for Glucagon-like peptide 1 (GLP 1) agonists, February 2017. PATIENT S NAME: PATIENT S ADDRESS: HOSPITAL NAME
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationCost Effectiveness of canagliflozin (Invokana )
Cost Effectiveness of canagliflozin (Invokana ) for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on therapy with other anti-hyperglycaemic agents including insulin,
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationTYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS
TYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS The aim of the Diabetes level 2 service is to provide a high quality service for safe initiation and optimization of injectable therapy within GP networks.
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationUpdated August /08/2020
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the management of adults with diabetes
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationFasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period
Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period Dr Ketan Dhatariya MBBS MSc MD MS FRCP Consultant in Diabetes and Endocrinology Norfolk and Norwich
More informationPeri-operative management of the surgical patient with diabetes GL059
DT Peri-operative management of the surgical patient with diabetes GL059 Approval Approval Group Job Title, Chair of Committee Date Anaesthetics Clinical Governance Chair Anaesthetic governance Nov 2016
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationOral Treatments for Type 2 Diabetes. Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes Prescribing Support Pharmacist Learning Outcomes Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose levels When to use each
More informationFrailty and Type 2 Diabetes Guidelines for clinicians
H.G. WELLS PROJECT Frailty and Type 2 Diabetes Guidelines for clinicians Victoria Ruszala victoria.ruszala@nhs.net H.G. Wells Project team Dugal T, Partington E. Kernow CCG Diabetes and Frailty Guideline
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Joyce Robson Learning Outcomes Think about the place of injectible therapies in diabetes Insulin therapy GLP1 antagonists Consider commonly used
More informationDiabetes Prescribing Guidelines for the Glycaemia management of Adults with Type 2 Diabetes
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationType 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options?
Patient decision aid Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options? nice.org.uk/guidance/ng28 Published: December 2015 About this decision
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Linda Burns Learning Outcomes Understand the place of injectible therapies in diabetes Understand when patients may require insulin therapy Consider
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationNew Medicine Assessment
New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2
More informationOral Treatments. SaminaAli Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes SaminaAli Prescribing Support Pharmacist Learning Outcomes National Guidance Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose
More informationPolicy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus Version No. Changes Made Version of July 2018 V0.5 Changes made to the policy following patient engagement including: - the
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationEnd of Life Diabetes Care
End of Life Diabetes Care Commissioned by Diabetes UK Supplementary Documents and Flowcharts Endorsed By: Diabetes Phases of End of Life and Medications A - Blue: All From Diagnosis Stable With Year Plus
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationLeicestershire Diabetes Guidelines: Insulin Therapy
Endorsed by Leicestershire Medicines Strategy Group Leicestershire Diabetes Guidelines: Insulin Therapy These guidelines are designed for use by those trained and competent in insulin initiation and management
More informationInpatient Diabetes 20/01/2015. What should I do? Hyperglycaemia why does it matter? Why are the BSLs unstable? BSL parameters
Hyperglycaemia why does it matter? Inpatient Diabetes Angela Sheu Endocrine Registrar St George Hospital Hyperglycaemia at admission is a predictor of mortality May be part of stress response (eg post
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationCare Bundle. Adult patients with Type 2 Diabetes
Care Bundle Adult patients with Type 2 Diabetes July 2014 What is a care bundle? A care bundle is a set of interventions that, when used together, significantly improve patient outcomes. The measures chosen
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationMedicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationdapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationBNF CHAPTER 6: ENDOCRINE SYSTEM
BNF CHAPTER 6: ENDOCRINE SYSTEM BNF 6.1.1 INSULINS First Choice Typical Dose Alternatives Typical Dose Neutral Protamine Hagedorn (NPH) insulin or Premixed biphasic insulin Titrate dose to patients needs
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationManaging Hyperglycaemia in Acute (Adult) Inpatients Requiring Enteral Feeding Guidelines
Document Control Title Managing Hyperglycaemia in Acute (Adult) Inpatients Requiring Author Author s job title Specialist Nurse Consultant Physician Department Directorate Unscheduled Care Version Date
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationNICE BULLETIN Type 2 diabetes in adults: management
NICE BULLETIN Type 2 diabetes in adults: management NICE approved the reproduction of its content for this booklet. NICE is independent of any company or product advertised. TYPE2_DIABETES.indd 1 09/02/2016
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationDiabetes and steroids: Storm conditions
Article Diabetes and steroids: Storm conditions June James Citation: James J (2016) Diabetes and steroids: Storm conditions. Journal of Diabetes Nursing 20: 128 33 Article points 1. Steroids are often
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More information